# Phase 1 Squamous Cell Carcinoma of: 82 recruiting (2026)

ClinicalTrials.gov lists 82 trials in phase 1 for Squamous Cell Carcinoma of Head and Neck that are recruiting or not yet recruiting.

## The full list

Recruiting Phase 1 Squamous Cell Carcinoma of Head and Neck trials: 82 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1/squamous-cell-carcinoma-of-head-and-neck

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 82
- Recruiting or not yet: 82
- Read on: November 19, 2026

## Trials

The 25 newest of 82, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 27, 2026 | NCT07898124 | TMV Vaccine Alone or With Toripalimab-tpzi for Recurrent Head and Neck Squamous Cell Carcinoma | Metaclipse Therapeutics Corporation | Phase 1 | Recruiting | Squamous Cell Carcinoma of Head and Neck, Squamous Cell Carcinoma of Head and Neck (SCCHN), HNSCC, Neoplasm Recurrence... | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07898124) |
| October 22, 2026 | NCT07887971 | A Study of \[225Ac\]Ac-AKY-2519 in Patients With B7-H3 Expressing Solid Tumors | Aktis Oncology, Inc. | Phase 1 | Recruiting | NSCLC, NSCLC (Advanced Non-small Cell Lung Cancer), ES-SCLC, Small Cell Lung Cancer Extensive Stage, B7H3, Prostate... | 152 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07887971) |
| October 15, 2026 | NCT07874880 | MTX-531-001 Phase 1 Study in Advanced Solid Tumors | MEKanistic Therapeutics, Inc. | Phase 1 | Not yet recruiting | Solid Tumors (Phase 1), HNSCC, Endometrial Cancer, Her2-negative Metastatic Breast Cancer, Pan-RAS and BRAF Wild-type... | 71 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07874880) |
| September 10, 2026 | NCT07814248 | A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a... | TwoStep Therapeutics, Inc. | Phase 1 | Recruiting | NSCLC (Non-small Cell Lung Cancer), HNSCC, Endometrial, Ovarian Cancer, Esophageal Cancer, Head & Neck Cancer, Gastric... | 74 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07814248) |
| September 8, 2026 | NCT07807956 | A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With... | AbbVie | Phase 1 | Recruiting | Advanced Solid Tumors, Non-Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Gastric Cancer... | 130 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07807956) |
| September 8, 2026 | NCT07807345 | Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic | Sutro Biopharma, Inc. | Phase 1 | Recruiting | Head & Neck Squamous Cell Carcinoma, Non-Small Cell Lung Cancer, Esophageal Cancer, Gastric Cancer, Colorectal Cancer... | 285 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07807345) |
| August 3, 2026 | NCT07741643 | Study Evaluating the Safety and Feasibility of Panitumumab-IRDye800 and \[18F\]NOTA-ABY-030 for Targeted Dual-Modality Imaging (TDMI) in Head... | Vanderbilt-Ingram Cancer Center | Phase 1 | Recruiting | HNSCC,Larynx, Pharynx and Oral Cavity, Squamous Cell Carcinoma, Head and Neck Cancer, Head and Neck Surgery | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07741643) |
| July 8, 2026 | NCT07690618 | Thermotherapy for Head and Neck Cancer Patients | Erasmus Medical Center | Phase 1 | Recruiting | Head and Neck Cancer, Oropharyngeal Carcinoma, Hypopharyngeal Carcinoma, Laryngeal Carcinoma, Head and Neck Squamous... | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07690618) |
| June 3, 2026 | NCT07623369 | A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors | Huahui Health | Phase 1 | Recruiting | Solid Tumor, Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Colorectal Cancer, Head and Neck Squamous Cell... | 299 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07623369) |
| May 15, 2026 | NCT07589205 | Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | Phase 1 | Recruiting | Solid Tumor, Colorectal Cancer, Non-small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Head and Neck Squamous... | 493 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07589205) |
| May 13, 2026 | NCT07584499 | Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors | Sun Yat-sen University | Phase 1 | Recruiting | Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Nasopharyngeal Carcinoma, Lymphoepithelial... | 51 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07584499) |
| May 5, 2026 | NCT07567235 | Clinical Study of CFH Protein Via Ice Microneedles for Radiation-Induced Skin Fibrosis | West China Hospital | Phase 1 | Recruiting | Radiation-Induced Skin Fibrosis, Head and Neck Squamous Cell Carcinoma | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07567235) |
| April 8, 2026 | NCT07517198 | Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | Phase 1 | Recruiting | Solid Tumor, Small Cell Lung Cancer (SCLC), High Grade Neuroendocrine Cancer, Small Cell Carcinomas of Non-lung Origin... | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07517198) |
| March 31, 2026 | NCT07503808 | A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types | IDEAYA Biosciences | Phase 1 | Recruiting | Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal... | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07503808) |
| March 10, 2026 | NCT07462377 | A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC | EpiBiologics | Phase 1 | Recruiting | Epidermal Growth Factor, Epidermal Growth Factor Receptor, Epidermal Growth Factor Receptor Gene Mutation, Non Small... | 110 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07462377) |
| March 10, 2026 | NCT07460765 | Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC) | Vanderbilt-Ingram Cancer Center | Phase 1 | Recruiting | Hnscc, Head and Neck, Squamous Cell Cancer, Squamous Carcinoma, Squamous Cell Cancer of Head and Neck (SCCHN), Squamous... | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07460765) |
| March 6, 2026 | NCT07455032 | Neoadjuvant CADI-05 in Combination With Pembrolizumab for Surgically Resectable Locally Advanced Head and Neck Squamous Cell Carcinomas | Fox Chase Cancer Center | Phase 1 | Recruiting | Squamous Cell Carcinoma of Head and Neck | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07455032) |
| January 22, 2026 | NCT07360314 | Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors | EMD Serono Research & Development Institute, Inc. | Phase 1 | Recruiting | Advanced Solid Tumors | 138 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07360314) |
| January 22, 2026 | NCT07358884 | First in Human Study of QLS5316 in Solid Tumors | Qilu Pharmaceutical Co., Ltd. | Phase 1 | Not yet recruiting | Solid Tumors, Colorectal Cancer, Gastric Cancer or Gastroesophageal Junction Adenocarcinoma, Head and Neck Squamous... | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07358884) |
| January 16, 2026 | NCT07348211 | First in Human Study of SIM0610 in Solid Tumors | Jiangsu Simcere Pharmaceutical Co., Ltd. | Phase 1 | Recruiting | Advanced Solid Tumours, Non-Small Cell Lung Cancer, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma... | 260 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07348211) |
| January 13, 2026 | NCT07335380 | Lattice-Based Radiotherapy and Chemo-Immunotherapy for Oral Cavity Squamous Cell Carcinoma | NYU Langone Health | Phase 1 | Not yet recruiting | Oral Cavity Squamous Cell Carcinoma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07335380) |
| December 12, 2025 | NCT07279116 | ABY-029 Head & Neck Phase 1 Trial | Dartmouth-Hitchcock Medical Center | Phase 1 | Recruiting | Head and Neck Squamous Cell Carcinoma | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07279116) |
| December 10, 2025 | NCT07274852 | A Study of Lutetium \[177Lu\]-BL-ARC001 in Patients With Locally Advanced or Metastatic Lung Cancer, Breast Cancer, Head and Neck Squamous... | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 1 | Recruiting | Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma, Solid Tumors | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07274852) |
| December 9, 2025 | NCT07272642 | A Phase 1, Multicenter Imaging Study of LNTH-2403 in Participants With Locally Advanced or Metastatic Solid Tumors. | Radiopharm Theranostics, Ltd | Phase 1 | Not yet recruiting | Imaging, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Non-Small Cell Lung Cancer, Triple Negative Breast... | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07272642) |
| November 21, 2025 | NCT07241039 | A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and... | AbbVie | Phase 1 | Recruiting | Advanced Squamous Tumors | 220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07241039) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Vanderbilt-Ingram Cancer Center | 6 |
| [AbbVie](https://specstream.ai/data/clinical-trials/company/abbvie) | 4 |
| [Sichuan Baili Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/sichuan-baili-pharmaceutical-co-ltd) | 3 |
| Memorial Sloan Kettering Cancer Center | 2 |
| West China Hospital | 2 |
| M.D. Anderson Cancer Center | 2 |
| [Seagen, a wholly owned subsidiary of Pfizer](https://specstream.ai/data/clinical-trials/company/seagen-a-wholly-owned-subsidiary-of-pfizer) | 2 |
| National Cancer Institute (NCI) | 1 |
| Radiopharm Theranostics, Ltd | 1 |
| SparX Biotech(Jiangsu) Co., Ltd. | 1 |
| Therorna | 1 |
| Nurix Therapeutics, Inc. | 1 |
| Emory University | 1 |
| ALX Oncology Inc. | 1 |
| [Exelixis](https://specstream.ai/data/clinical-trials/company/exelixis) | 1 |
| [Pfizer](https://specstream.ai/data/clinical-trials/company/pfizer) | 1 |
| IDEAYA Biosciences | 1 |
| Zumutor Biologics Inc. | 1 |
| TwoStep Therapeutics, Inc. | 1 |
| Aktis Oncology, Inc. | 1 |
| Johnson & Johnson Enterprise Innovation Inc. | 1 |
| Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | 1 |
| Bicara Therapeutics | 1 |
| VLP Therapeutics | 1 |
| Calico Life Sciences LLC | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 62 |
| China | 16 |
| Australia | 11 |
| Spain | 11 |
| Japan | 9 |
| United Kingdom | 8 |
| France | 7 |
| Canada | 6 |
| South Korea | 6 |
| Israel | 5 |
| Taiwan | 5 |
| Italy | 3 |
| Austria | 2 |
| Belgium | 2 |
| Germany | 2 |
| Switzerland | 2 |
| Puerto Rico | 2 |
| Netherlands | 2 |
| New Zealand | 1 |
| Poland | 1 |
| Georgia | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Bathroom remodelers in the United States](https://specstream.ai/data/businesses/bathroom-remodelers/united-states)
- [Diners in the United States](https://specstream.ai/data/businesses/diners/united-states)
- [Handyman services in the United States](https://specstream.ai/data/businesses/handyman-services/united-states)
- [Medical supply stores in the United States](https://specstream.ai/data/businesses/medical-supply-stores/united-states)
- [Public relations firms in the United States](https://specstream.ai/data/businesses/public-relations-firms/united-states)
- [Tree services in the United States](https://specstream.ai/data/businesses/tree-services/united-states)
